What is Pathmaker Neurosystems?
PathMaker Neurosystems is a clinical-stage company dedicated to pioneering non-invasive neuromodulation devices for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other severe neurological conditions. The company's innovative approach centers on suppressing neuronal hyperexcitability and activating protein degradation pathways. By leveraging advanced multi-site direct current stimulation technology, PathMaker aims to facilitate the restoration of damaged neural pathways and mitigate protein aggregation within motor neurons. This strategy, supported by extensive pre-clinical and clinical research, positions PathMaker Neurosystems at the vanguard of developing novel therapeutic paradigms for ALS.
How much funding has Pathmaker Neurosystems raised?
Pathmaker Neurosystems has raised a total of $2.2M across 2 funding rounds:
Debt
$36K
Other Financing Round
$2.2M
Debt (2021): $36K with participation from PPP
Other Financing Round (2024): $2.2M, investors not publicly disclosed
Key Investors in Pathmaker Neurosystems
PPP
Public-Private Partnership
What's next for Pathmaker Neurosystems?
With the recent infusion of major strategic capital, PathMaker Neurosystems is poised to accelerate its commercialization efforts for its innovative neuromodulation devices. The enterprise-level funding suggests a focus on scaling operations, expanding clinical trials, and potentially forging strategic partnerships to broaden market access. This investment will likely fuel further research and development, aiming to solidify its position as a leader in neurological disorder treatments and bring its non-invasive solutions to patients in need.
See full Pathmaker Neurosystems company page
